Crown Wealth Group, LLC Apellis Pharmaceuticals, Inc. Transaction History

Crown Wealth Group, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 25, 2023	SELL	$76.68 - $93.31 $53,676 - $65,317	-700 Reduced 12.96%	4,700 $428,000
Q1 2023 Apr 28, 2023	SELL	$46.59 - $66.96 $298,828 - $429,481	-6,414 Reduced 54.29%	5,400 $356,000
Q4 2022 Feb 09, 2023	BUY	$43.24 - $61.04 $295,761 - $417,513	6,840 Added 137.52%	11,814 $610,000
Q3 2022 Oct 21, 2022	BUY	$44.76 - $69.66 $222,636 - $346,488	4,974 New	4,974 $340,000
Q1 2022 Jul 13, 2022	SELL	$35.46 - $54.12 $178,718 - $272,764	-5,040 Closed	0 $0
Q4 2021 Jul 13, 2022	BUY	$30.74 - $49.16 $154,929 - $247,766	5,040 New	5,040 $238,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Crown Wealth Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Crown Wealth Group, LLC with notifications on news.